Do analysts prefer SNYR or FNCH?

Synergy CHC presently has a consensus target price of $6.25, suggesting a potential upside of 3,088.78%. Given Synergy CHC's stronger consensus rating and higher possible upside, analysts clearly believe Synergy CHC is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend SNYR or BON?

Synergy CHC presently has a consensus target price of $6.25, suggesting a potential upside of 3,088.78%. Given Synergy CHC's stronger consensus rating and higher probable upside, analysts plainly believe Synergy CHC is more favorable than Bon Natural Life. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, SNYR or BON?

Bon Natural Life has lower revenue, but higher earnings than Synergy CHC. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synergy CHC $30.38M 0.10 -$12.34M -$1.40 N/A Bon Natural Life $18.67M 0.59 -$2M N/A N/A

Does the media favor SNYR or BON?

In the previous week, Synergy CHC had 9 more articles in the media than Bon Natural Life. MarketBeat recorded 12 mentions for Synergy CHC and 3 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 1.38 beat Synergy CHC's score of -0.47 indicating that Bon Natural Life is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synergy CHC 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bon Natural Life 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KPRX or SNYR?

In the previous week, Synergy CHC had 10 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 12 mentions for Synergy CHC and 2 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 1.33 beat Synergy CHC's score of -0.47 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiora Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Synergy CHC 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BFRI or SNYR?

Synergy CHC has a consensus price target of $6.25, suggesting a potential upside of 3,088.78%. Given Synergy CHC's stronger consensus rating and higher possible upside, analysts plainly believe Synergy CHC is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Synergy CHC 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher valuation and earnings, BFRI or SNYR?

Biofrontera has higher revenue and earnings than Synergy CHC. Biofrontera is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biofrontera $41.71M 0.27 -$10.54M -$0.97 N/A Synergy CHC $30.38M 0.10 -$12.34M -$1.40 N/A

Is BFRI or SNYR more profitable?

Biofrontera has a net margin of -25.66% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of -19.51% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets Biofrontera -25.66% -515.34% -53.91% Synergy CHC -60.02% -19.51% -30.30%

Does the media refer more to BFRI or SNYR?

In the previous week, Synergy CHC had 9 more articles in the media than Biofrontera. MarketBeat recorded 12 mentions for Synergy CHC and 3 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.18 beat Synergy CHC's score of -0.47 indicating that Biofrontera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Synergy CHC 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate MTEX or SNYR?

Synergy CHC has a consensus target price of $6.25, suggesting a potential upside of 3,088.78%. Given Synergy CHC's stronger consensus rating and higher probable upside, analysts clearly believe Synergy CHC is more favorable than Mannatech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synergy CHC 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is MTEX or SNYR more profitable?

Mannatech has a net margin of -11.97% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of -19.51% beat Mannatech's return on equity. Company Net Margins Return on Equity Return on Assets Mannatech -11.97% -2,383.34% -40.24% Synergy CHC -60.02% -19.51% -30.30%

Does the media refer more to MTEX or SNYR?

In the previous week, Synergy CHC had 10 more articles in the media than Mannatech. MarketBeat recorded 12 mentions for Synergy CHC and 2 mentions for Mannatech. Mannatech's average media sentiment score of 0.93 beat Synergy CHC's score of -0.47 indicating that Mannatech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mannatech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Synergy CHC 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Synergy CHC (SNYR) Competitors

$0.20 0.00 (0.00%)

As of 06/12/2026 04:00 PM Eastern

Compare

SNYR vs. FNCH, BON, KPRX, BFRI, and MTEX

Should you buy Synergy CHC stock or one of its competitors? MarketBeat compares Synergy CHC with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Synergy CHC include Finch Therapeutics Group (FNCH), Bon Natural Life (BON), Kiora Pharmaceuticals (KPRX), Biofrontera (BFRI), and Mannatech (MTEX). These companies are all part of the "pharmaceutical products" industry.

How does Synergy CHC compare to Finch Therapeutics Group?

Synergy CHC (NASDAQ:SNYR) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Synergy CHC presently has a consensus target price of $6.25, suggesting a potential upside of 3,088.78%. Given Synergy CHC's stronger consensus rating and higher possible upside, analysts clearly believe Synergy CHC is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synergy CHC	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Synergy CHC has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synergy CHC	$30.38M	0.10	-$12.34M	-$1.40	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

21.8% of Finch Therapeutics Group shares are held by institutional investors. 32.9% of Synergy CHC shares are held by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Finch Therapeutics Group has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of -19.51% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synergy CHC	-60.02%	-19.51%	-30.30%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

Synergy CHC has a beta of -0.27, meaning that its stock price is 127% less volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

In the previous week, Synergy CHC had 12 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 12 mentions for Synergy CHC and 0 mentions for Finch Therapeutics Group. Finch Therapeutics Group's average media sentiment score of 0.00 beat Synergy CHC's score of -0.47 indicating that Finch Therapeutics Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Synergy CHC	Neutral
Finch Therapeutics Group	Neutral

Summary

Synergy CHC beats Finch Therapeutics Group on 9 of the 15 factors compared between the two stocks.

How does Synergy CHC compare to Bon Natural Life?

Synergy CHC (NASDAQ:SNYR) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

0.6% of Bon Natural Life shares are held by institutional investors. 32.9% of Synergy CHC shares are held by company insiders. Comparatively, 26.5% of Bon Natural Life shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bon Natural Life has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Bon Natural Life's return on equity of 0.00% beat Synergy CHC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synergy CHC	-60.02%	-19.51%	-30.30%
Bon Natural Life	N/A	N/A	N/A

Synergy CHC presently has a consensus target price of $6.25, suggesting a potential upside of 3,088.78%. Given Synergy CHC's stronger consensus rating and higher probable upside, analysts plainly believe Synergy CHC is more favorable than Bon Natural Life.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synergy CHC	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Synergy CHC had 9 more articles in the media than Bon Natural Life. MarketBeat recorded 12 mentions for Synergy CHC and 3 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 1.38 beat Synergy CHC's score of -0.47 indicating that Bon Natural Life is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synergy CHC	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bon Natural Life	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Synergy CHC has a beta of -0.27, indicating that its share price is 127% less volatile than the broader market. Comparatively, Bon Natural Life has a beta of -0.17, indicating that its share price is 117% less volatile than the broader market.

Bon Natural Life has lower revenue, but higher earnings than Synergy CHC.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synergy CHC	$30.38M	0.10	-$12.34M	-$1.40	N/A
Bon Natural Life	$18.67M	0.59	-$2M	N/A	N/A

Summary

Bon Natural Life beats Synergy CHC on 8 of the 14 factors compared between the two stocks.

How does Synergy CHC compare to Kiora Pharmaceuticals?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Kiora Pharmaceuticals has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of -19.51% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%
Synergy CHC	-60.02%	-19.51%	-30.30%

Kiora Pharmaceuticals has a beta of -0.4, meaning that its stock price is 140% less volatile than the broader market. Comparatively, Synergy CHC has a beta of -0.27, meaning that its stock price is 127% less volatile than the broader market.

In the previous week, Synergy CHC had 10 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 12 mentions for Synergy CHC and 2 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 1.33 beat Synergy CHC's score of -0.47 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiora Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Synergy CHC	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kiora Pharmaceuticals has higher earnings, but lower revenue than Synergy CHC. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	N/A	N/A	-$10.84M	-$2.71	N/A
Synergy CHC	$30.38M	0.10	-$12.34M	-$1.40	N/A

Kiora Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 292.16%. Synergy CHC has a consensus target price of $6.25, suggesting a potential upside of 3,088.78%. Given Synergy CHC's stronger consensus rating and higher possible upside, analysts clearly believe Synergy CHC is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synergy CHC	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 0.1% of Kiora Pharmaceuticals shares are held by insiders. Comparatively, 32.9% of Synergy CHC shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Synergy CHC beats Kiora Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Synergy CHC compare to Biofrontera?

Biofrontera (NASDAQ:BFRI) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Synergy CHC had 9 more articles in the media than Biofrontera. MarketBeat recorded 12 mentions for Synergy CHC and 3 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.18 beat Synergy CHC's score of -0.47 indicating that Biofrontera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biofrontera	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Synergy CHC	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biofrontera has higher revenue and earnings than Synergy CHC. Biofrontera is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.27	-$10.54M	-$0.97	N/A
Synergy CHC	$30.38M	0.10	-$12.34M	-$1.40	N/A

Biofrontera has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Synergy CHC has a beta of -0.27, indicating that its stock price is 127% less volatile than the broader market.

10.1% of Biofrontera shares are held by institutional investors. 8.1% of Biofrontera shares are held by company insiders. Comparatively, 32.9% of Synergy CHC shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Biofrontera has a net margin of -25.66% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of -19.51% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
Synergy CHC	-60.02%	-19.51%	-30.30%

Synergy CHC has a consensus price target of $6.25, suggesting a potential upside of 3,088.78%. Given Synergy CHC's stronger consensus rating and higher possible upside, analysts plainly believe Synergy CHC is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synergy CHC	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Biofrontera and Synergy CHC tied by winning 8 of the 16 factors compared between the two stocks.

How does Synergy CHC compare to Mannatech?

Mannatech (NASDAQ:MTEX) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Synergy CHC has lower revenue, but higher earnings than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04M	0.10	-$15.21M	-$6.71	N/A
Synergy CHC	$30.38M	0.10	-$12.34M	-$1.40	N/A

Synergy CHC has a consensus target price of $6.25, suggesting a potential upside of 3,088.78%. Given Synergy CHC's stronger consensus rating and higher probable upside, analysts clearly believe Synergy CHC is more favorable than Mannatech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synergy CHC	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Mannatech has a net margin of -11.97% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of -19.51% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mannatech	-11.97%	-2,383.34%	-40.24%
Synergy CHC	-60.02%	-19.51%	-30.30%

In the previous week, Synergy CHC had 10 more articles in the media than Mannatech. MarketBeat recorded 12 mentions for Synergy CHC and 2 mentions for Mannatech. Mannatech's average media sentiment score of 0.93 beat Synergy CHC's score of -0.47 indicating that Mannatech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mannatech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Synergy CHC	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

13.0% of Mannatech shares are held by institutional investors. 41.5% of Mannatech shares are held by company insiders. Comparatively, 32.9% of Synergy CHC shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Mannatech has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market. Comparatively, Synergy CHC has a beta of -0.27, indicating that its share price is 127% less volatile than the broader market.

Summary

Synergy CHC beats Mannatech on 9 of the 16 factors compared between the two stocks.

Get Synergy CHC News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNYR vs. The Competition

Export

Metric	Synergy CHC	CONS PD Industry	Staples Sector	NASDAQ Exchange
Market Cap	$2.96M	$30.81B	$16.56B	$12.05B
Dividend Yield	N/A	3.21%	3.40%	5.66%
P/E Ratio	-0.14	74.14	26.53	24.42
Price / Sales	0.10	1.62	47.25	118.72
Price / Cash	N/A	13.44	13.38	37.92
Price / Book	-0.10	10.83	5.61	6.82
Net Income	-$12.34M	$1.30B	$683.11M	$337.56M
7 Day Performance	-5.72%	8.17%	3.28%	1.16%
1 Month Performance	-31.64%	18.77%	3.59%	3.16%
1 Year Performance	-90.58%	-10.69%	-9.13%	30.60%

Synergy CHC Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNYR Synergy CHC	2.1379 of 5 stars	$0.20 flat	$6.25 +3,088.8%	-90.6%	$2.96M	$30.38M	N/A	40	News Coverage Analyst Revision
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190
BON Bon Natural Life	1.1204 of 5 stars	$1.44 +9.3%	N/A	-11.8%	$11.71M	$18.67M	N/A	100	Positive News Short Interest Decrease Gap Up High Trading Volume
KPRX Kiora Pharmaceuticals	3.6382 of 5 stars	$2.60 +0.4%	$10.00 +284.6%	-15.6%	$11.52M	$16.02M	N/A	10	Positive News
BFRI Biofrontera	1.6435 of 5 stars	$0.88 -0.6%	N/A	+31.3%	$11.20M	$41.71M	N/A	70	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNYR) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synergy CHC (SNYR) Competitors

SNYR vs. FNCH, BON, KPRX, BFRI, and MTEX

How does Synergy CHC compare to Finch Therapeutics Group?

Summary

How does Synergy CHC compare to Bon Natural Life?

Summary

How does Synergy CHC compare to Kiora Pharmaceuticals?

Summary

How does Synergy CHC compare to Biofrontera?

Summary

How does Synergy CHC compare to Mannatech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNYR vs. The Competition

Synergy CHC Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synergy CHC (SNYR) Competitors

SNYR vs. FNCH, BON, KPRX, BFRI, and MTEX

How does Synergy CHC compare to Finch Therapeutics Group?

Do analysts prefer SNYR or FNCH?

Which has better earnings & valuation, SNYR or FNCH?

Do insiders & institutionals believe in SNYR or FNCH?

Is SNYR or FNCH more profitable?

Which has more volatility & risk, SNYR or FNCH?

Does the media favor SNYR or FNCH?

Summary

How does Synergy CHC compare to Bon Natural Life?

Do institutionals and insiders hold more shares of SNYR or BON?

Is SNYR or BON more profitable?

Do analysts recommend SNYR or BON?

Does the media favor SNYR or BON?

Which has more volatility & risk, SNYR or BON?

Which has better valuation and earnings, SNYR or BON?

Summary

How does Synergy CHC compare to Kiora Pharmaceuticals?

Is KPRX or SNYR more profitable?

Which has more risk and volatility, KPRX or SNYR?

Does the media refer more to KPRX or SNYR?

Which has stronger earnings and valuation, KPRX or SNYR?

Do analysts prefer KPRX or SNYR?

Do institutionals and insiders have more ownership in KPRX or SNYR?

Summary

How does Synergy CHC compare to Biofrontera?

Does the media refer more to BFRI or SNYR?

Which has higher valuation and earnings, BFRI or SNYR?

Which has more volatility and risk, BFRI or SNYR?

Do institutionals & insiders have more ownership in BFRI or SNYR?

Is BFRI or SNYR more profitable?

Do analysts rate BFRI or SNYR?

Summary

How does Synergy CHC compare to Mannatech?

Which has preferable earnings & valuation, MTEX or SNYR?

Do analysts rate MTEX or SNYR?

Is MTEX or SNYR more profitable?

Does the media refer more to MTEX or SNYR?

Do insiders & institutionals have more ownership in MTEX or SNYR?

Which has more volatility & risk, MTEX or SNYR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNYR vs. The Competition

Synergy CHC Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools